Análisis de los problemas relacionados con los medicamentos en un hospital de tercer nivel de Barcelona

Ferránzez Quirante, Olivia; Casañ, Borja; Grau Cerrato, Santiago; Louro, Javier; Salas Sanchez, Esther; Castells, Xavier; Sala Serra, Maria

doi:http://dx.doi.org/10.1016/j.gaceta.2018.01.002

Análisis de los problemas relacionados con los medicamentos en un hospital de tercer nivel de Barcelona

License

Citation

Ferrández O, Casañ B, Grau S, Louro J, Salas E, Castells X et al. Análisis de los problemas relacionados con los medicamentos en un hospital de tercer nivel de Barcelona. Gac Sanit. 2019 Jul - Aug;33(4):361-8. DOI: 10.1016/j.gaceta.2018.01.002

Abstract

OBJECTIVE: To describe drug-related problems identified in hospitalized patients and to assess physicians' acceptance rate of pharmacists' recommendations. METHODS: Retrospective observational study that included all drug-related problems detected in hospitalized patients during 2014-2015. Statistical analysis included a descriptive analysis of the data and a multivariate logistic regression to evaluate the association between pharmacists' recommendation acceptance rate and the variable of interest. RESULTS: During the study period 4587 drug-related problems were identified in 44,870 hospitalized patients. Main drug-related problems were prescription errors due to incorrect use of the computerized physician order entry (18.1%), inappropriate drug-drug combination (13.3%) and dose adjustment by renal and/or hepatic function (11.5%). Acceptance rate of pharmacist therapy advice in evaluable cases was 81.0%. Medical versus surgical admitting department, specific types of intervention (addition of a new drug, drug discontinuation and correction of a prescription error) and oral communication of the recommendation were associated with a higher acceptance rate. CONCLUSIONS: The results of this study allow areas to be identified on which to implement optimization strategies. These include training courses for physicians on the computerized physician order entry, on drugs that need dose adjustment with renal impairment, and on relevant drug interactions.